Fig. 8: LUXendin645 labels human ESC-derived β-like cells.

a LUXendin645 (LUX645) labels β-like cells in intact spheroids, which were differentiated and cultured for 21 days. No signal is detected in undifferentiated human ES cells (day 0) or unlabelled β-like cells (-LUX645) (representative images from n = 6 spheroids) (scale bar = 100 µm). b GLP1R gene expression in day 0 undifferentiated cells, day 21 differentiated β-like cells, and human islets (n = 3 donors). c LUXendin645 labelling is localized to strongly insulin (INS)-positive but not strongly glucagon (GCG)-positive areas (representative images from n = 5–6 spheroids) (scale bar = 50 µm). d LUXendin645 (LUX) overlaps more with INS vs. GCG, as calculated using Manders’ M1 co-efficient (n = 5–6 spheroids) (unpaired Student’s t-test). e Day 21 spheroid sections (5 µm) showing expression of INS and NKX6-1, confirming a differentiated phenotype (representative images from n = 4 spheroids) (scale bar = 100 µm). f FACS plots of day 21 β-like cells with and without LUXendin645 (LUX645) incubation. LUXendin645+ (LUX+) and LUXendin645− (LUX−) cells were sorted for qPCR. g GLP1R, NKX6-1, INS, and GCG gene expression in sorted cells (n = 4 spheroids) (connecting bars indicate LUX+ and LUX− populations in the same samples) (paired Student’s t-test). LUXendin645 was applied at 100 nM. Mean ± s.e.m. are shown. *P < 0.05, **P < 0.01 for all statistical tests. Source data are provided as a Source Data file.